This tracker summarizes publicly discussed research-peptide vendor exits and enforcement-adjacent events so laboratories can cross-check procurement risk. Entries are not accusations of wrongdoing unless linked to a primary source. PurePep Vital does not sell peptides and does not conduct vendor investigations.
Regulatory and criminal matters must be verified on FDA.gov, court systems, and with your compliance team. Forum threads and blogs are not evidence.
| Vendor | Period | Public context | Laboratory takeaway |
|---|---|---|---|
| Peptide Sciences | 2026 (reported) | Widely discussed wind-down of a long-running research peptide catalog brand. Industry forums and buyer communities reported halted new orders and fulfillment uncertainty in early 2026. | Treat historical COAs and batch records as archival. Verify any successor entity or domain before purchasing. PurePep Vital lists EZ Peptides as an active independent alternative in current vendor comparisons. |
| Science.bio | 2021–2022 (historical) | Historical shutdown of a prominent research chemical supplier; frequently cited in retrospectives on sector consolidation and documentation norms. | Use only as precedent for why batch documentation and supplier continuity matter. Not actionable for current procurement. |
| Amino Asylum | 2025 (public reporting) | Public reporting described FDA regulatory interest and related enforcement activity affecting certain research chemical sellers. Details vary by source and time. | Verify facts against FDA.gov press announcements, court dockets, and institutional counsel. Do not rely on forum posts alone for compliance decisions. |
| Paradigm Peptides | 2025 (public reporting) | Trade press and public court filings discussed legal exposure in the research peptide retail segment. Outcomes may be ongoing. | Institutional buyers should file vendor risk reviews using primary legal sources, not second-hand summaries. |